This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intuitive Surgical to Boost da Vinci Platform With Buyout
by Zacks Equity Research
Intuitive Surgical's (ISRG) acquisition of Scholly Fiberoptic's robotic endoscope business to likely boost the acquirer's da Vinci Surgical system.
Five Surging Strong Buy Stocks To Watch
by David Bartosiak
Despite the market selling off today, these five strong buys are red hot.
Moving Average Crossover Alert: Haemonetics
by Zacks Equity Research
Haemonetics Corporation (HAE) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Varian (VAR) Installs ProBeam Compact in Thailand's Hospital
by Zacks Equity Research
Varian (VAR) gains from a slew of recent developments in its Proton Therapy platform.
Varian (VAR) to Boost Cancer Treatment With New Partnership
by Zacks Equity Research
Varian (VAR) expects to enhance cancer care with the new collaboration with IAEA, which is likely to drive Varian's core Oncology business.
Here's Why You Should Invest in Wright Medical Stock Now
by Zacks Equity Research
Wright Medical (WMGI) continues to benefit from strong international sales, new product launches and solid prospects in the global Orthopedic space.
Will MedTech Ease Investors' Concern & Outperform? 4 Picks
by Urmimala Biswas
Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.
Here's Why You Should Invest in CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.
Smith & Nephew Acquires Atracsys, Expands Robotic Portfolio
by Zacks Equity Research
With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.
Luminex (LMNX) Presents ARIES MRSA Assay to FDA for Clearance
by Zacks Equity Research
Luminex (LMNX) submits the ARIES MRSA assay to the FDA for clearance. The company's ARIES system will get a substantial boost once the FDA clearance is through.
Here's Why You Should Hold on to Nevro (NVRO) Stock Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, severe rivalry is a lingering woe.
Here's Why You Should Retain Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
HealthEquity (HQY) Set to Acquire WageWorks for $2 Billion
by Zacks Equity Research
HealthEquity (HQY) is set to acquire WageWorks in an all-cash deal of about $2 billion. The buyout is expected to help HealthEquity to expedite the market-wide transition to HSAs.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market.
Here's Why You Should Retain Allscripts (MDRX) Stock Now
by Zacks Equity Research
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Here's Why You Should Invest in Cooper Companies Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) is gaining steadily from strong international growth and robust product portfolio. However, unfavorable pricing environment remains a woe.
Haemonetics on a High Owing to Firm Plasma Arm, Global Growth
by Zacks Equity Research
Continued traction in new business wins and expansion of geographies are lifting Haemonetics' (HAE) performance of late.
Here's Why You Should Invest in Haemonetics (HAE) Stock Now
by Zacks Equity Research
Haemonetics (HAE) benefits from impressive uptick of Hemostasis Management revenues.
Haemonetics' Plant Sell-Off to CLS Plasma to be Strategic Fit
by Zacks Equity Research
This impending divestment remains integral to Haemonetics' (HAE) asset optimization strategy that aims at improving its operational performance and focusing on core competencies.
AMN Healthcare (AMN) Closes Advanced Medical Acquisition
by Zacks Equity Research
AMN Healthcare (AMN) completes Advanced Medical buyout that will help the former to boost offerings in some of the fastest growing and very important care settings.
Agios (AGIO) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Agios (AGIO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Here's Why You Should Hold on to PRA Health (PRAH) Stock Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.
Will Haemonetics Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Haemonetics.